NCT05673460

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

A Phase 1 Clinical Study of Nemtabrutinib (MK-1026) in Japanese Participants With Hematological Malignancies (BELLWAVE-002)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of nemtabrutinib in Japanese participants with mature B-cell neoplasms.

Conditions

• Mature B-cell Neoplasms

Interventions

Type	Name	Description
DRUG	Nemtabrutinib	Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg

Timeline

• Start date: 2023-02-13
• Primary completion: 2025-04-28
• Completion: 2025-09-03
• First posted: 2023-01-06
• Last updated: 2025-09-16

Locations

7 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study